Clinical Trials · NCT04108208
A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- Janssen Research & Development, LLC
- Enrollment
- 75
- Start date
- Dec 2019
- Locations
- 27 sites, China
- Primary endpoint
- Time to Prostate Specific Antigen (PSA) Progression (TTPP) Based on Prostate Cancer Working Group 2 (PCWG2) Criteria